Monitoring Response to Tyrosine Kinase Inhibitor Therapy, Mutational Analysis, and New Treatment Options in Chronic Myelogenous Leukemia

Author:
Jerald P. Radich Presented by Jerald P. Radich, MD, Director of the Molecular Oncology Lab, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington.

Search for other papers by Jerald P. Radich in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 11: Issue 5S
Online Publication Date:
May 2013
DOI:
https://doi.org/10.6004/jnccn.2013.0196
Restricted access

Unlike in other leukemias, survival rates have climbed dramatically in early-phase chronic myelogenous leukemia (CML). This improvement in long-term prognosis is primarily the result of the tyrosine kinase inhibitor (TKI) imatinib and its second-generation cousins nilotinib and dasatinib. In his presentation at the NCCN 18th Annual Conference, Dr. Jerald P. Radich reviewed the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommendations for monitoring response to treatment with the TKIs, which center on complete cytogenetic response, and the role of mutational analysis for guiding treatment decisions in the setting of imatinib resistance. He also offered a brief mention of 2 new agents recently approved for resistant CML—ponatinib and bosutinib.

Correspondence: Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D4-100, Seattle, WA 98109-1024. E-mail: jradich@fhcrc.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Quintás-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.

  • 2.

    Druker BJ, Guilhot F, O‘Brien SG et al.. Five years follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.

  • 3.

    Deininger M, O‘Brien SG, Guilhot F et al.. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood 2009;114(Suppl): Abstract 1126.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Larson RA, Hochhaus A, Hughes TP et al.. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197–2203.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hochhaus A, Shah NP, Cortes JE et al.. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: DASISION 3-year follow-up [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw 2012;10(Suppl 3):S1–S13.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Baccarani M, Cortes J, Pane F et al.. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Marin D, Milojkovic D, Olavarria E et al.. European LeukemiaNet criteria for failure of suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437–4444.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mahon FX, Rea D, Guilhot J et al.. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained completed molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Cortes JE, Kim D-W, Pinilla-Ibarz J et al.. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6503.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Gambacorti-Passerini C, Lipton JH, Tee GY et al.. BELA trial update: bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia after 30 months of follow-up [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 6512.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2013 by the National Comprehensive Cancer Network 2013
Page Numbers:
4
Article Category:
Research Article
Print Publication Date:
01 May 2013
Online Publication Date:
May 2013

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 795 394 24
PDF Downloads 179 52 8
EPUB Downloads 0 0 0